| Revenue growth | INR 3,373 Cr in FY26 |
|---|---|
| Margins | EBITDA margin improved from 5.4% to 18.6% |
| Demand visibility | Strong for insulin and anti-MRSA brands |
| Management confidence | High regarding Zaynich US FDA/CDSCO approvals |
Growth
51% YoY EBITDA growth; Income at INR 3,373 Cr. Emrok grew ~50%; Biotech business grew 27%.
Outlook
Launching Zaynich in US, India, Europe; doubling Human Insulin capacity; deepening biosimilars pipeline.
Risks
Antimicrobial resistance challenges, IP risks, and R&D process uncertainties.
Last quarter's promises, checked
Delivered
- Guided 20% Zaynich superiority → delivered 20% (= BEAT)
- Guided INR 1000 Cr QIP → delivered INR 1000 Cr (= BEAT)
- Guided EBITDA growth >60% → delivered 67% (= BEAT)
Partly delivered
- Guided Zaynich US launch FY26-27 → delivered US FDA approval (= PARTIAL)
- Guided 2x Insulin capacity in 24mo → delivered 2x scale-up (= PARTIAL)
Missed
- Guided Net Debt:Equity 0.01% → delivered 0.10% (= MISS)
- Guided Revenue INR 3033 Cr → delivered INR 3373 Cr (= BEAT)
Earnings Call filed with NSE, NSE: WOCKPHARMA. Summary written with AI assistance from the document.
Wockhardt Ltd: key numbers
- Share price
- ₹2,137.20
- Market cap
- ₹34,728 Cr
- Revenue (annual)
- ₹3,373 Cr
- Net profit (annual)
- ₹213.0 Cr
- P/E (TTM)
- 84.9×Sector 47.4×
- Promoter holding
- 49.08%+0.00% QoQ
- FII holding
- 7.23%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wockhardt Ltd
All →Wockhardt Legal & Regulatory
Wockhardt Limited received an order from the Commissioner of Customs imposing a ₹5 Crore penalty and ₹10 Crore redemption fine. The company plans to challenge this order.
- Value
- ₹15.00 Cr
Wockhardt Legal & Regulatory
Wockhardt Limited received an adjudication order from the Commissioner of Customs imposing penalties and redemption fines aggregating to ₹16 Crore regarding API mis-classification.
- Value
- ₹16.00 Cr
Wockhardt Other Announcement
Wockhardt Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms no deviation in the utilization of QIP proceeds.
Wockhardt Business Update
Wockhardt Limited launched the 'Wockhardt Antibiotic Academy,' an open scientific learning platform aimed at facilitating knowledge exchange to tackle multidrug resistance among healthcare professionals.
Wockhardt Q1 FY27 Results: Turns Profitable, Net Profit ₹107 Cr
Wockhardt Ltd reported revenue from operations of ₹929 Cr (+25.9% YoY) and net profit of ₹107 Cr for Q1 FY27.
- Key figure
- Net profit ₹107 Cr
Wockhardt Annual General Meeting
Wockhardt Limited issued an AGM notice for August 10, 2026. The agenda includes approval for raising up to ₹3,000 Crore via QIP.
- Value
- ₹3,000 Cr